Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Researchers have identified a mechanistic link between SARS-CoV-2 infection and multisystem inflammatory syndrome in children, providing evidence for the involvement of molecular mimicry.
In a new study, researchers use M2 macrophage exosomes and membranes to disguise a tri-drug-carrying nanosystem that reduces inflammation and urate levels in rats with gouty arthritis.
The PDZ domain-containing scaffold protein PDZK1 is downregulated in osteoarthritic chondrocytes and is linked to mitochondrial dysfunction and chondrocyte senescence.
Two studies have identified variants of UNC93B1 that are associated with enhanced TLR7 and TLR8 activity and the development of systemic lupus erythematosus.
Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.
New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.
Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
A wearable smart device that uses reconfigurable electronics and conductive polymer-based microneedles was able to monitor inflammation and provide transdermal drug delivery and electrical stimulation in a rat model of arthritis.
Researchers have introduced the term ‘MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic’ (MIP-C) to describe cases of MDA5 autoimmunity that surged during the COVID-19 pandemic.
New research provides a potential explanation for why long-term sclerostin neutralization leads to continued bone mass gain, despite attenuation of its short-term effects on bone formation.
The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.
In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.
A nanoparticle-based formulation of the anticancer drug pazopanib, which inhibits VEGFR1 and VEGFR2, shows promise as a disease-modifying drug for osteoarthritis.
